BTG is a leader in interventional medicine treatments, which include inserting tiny devices into the body using minimally invasive surgery to treat diseases. BTG’s interventional medicine portfolio will boost Boston Scientific’s offerings in areas like cancer and pulmonary embolism.
While Boston Scientific expressed excitement about the interventional medicine treatments, it said it’s still considering what to do with BTG’s pharmaceutical business, which focuses on antidote products.
Boston Scientific has a market value of nearly $50 billion and has made nearly 20 acquisitions in the last five years. BTG, during the first six months ended Sept. 30, reported sales of $495.7 million.
Read the full report here.
More articles on supply chain:
Samsung Galaxy wants to help patients manage insulin therapy
Red Cross issues call for blood donations ahead of holidays
FDA’s cybersecurity policies for postmarket medical devices are ‘insufficient,’ OIG finds
